Conversely, liver cancer preferentially acquires mutations in CTNNB1 (25%) and AXIN1 (8%), while pancreatic cancers often harbor RNF43 (6%) mutations, and adrenocortical cancers show mutations in ZNRF3 (20%) or CTNNB1 (15%).314 The impact of genetic alterations in the Wnt pathway on cancer development is likely more significant than current databases reflect, underscoring the need for further investigation into these mutations (Table 2). This evidence concerns the gene ZNRF3 and adrenal cortex carcinoma.